Tested adaptive dosing of vismodegib for advanced skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an adaptive (adjusted) dosing plan using vismodegib for people with advanced basal cell carcinoma. It may help control the cancer while balancing side effects, and your team will closely monitor how your tumors respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed locally advanced basal cell carcinoma (diagnosed by biopsy/pathology).
- You’re age 18 or older and able/willing to sign consent papers.
- You have at least one skin tumor spot that can be measured with a ruler or calipers.
- Your general health is good enough (ECOG 0–2).
- You can take capsules and you do not have a known allergy to vismodegib.
- You must use strong pregnancy prevention rules during treatment and for a long time after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
This study registers people in the Netherlands who have certain types of basal cell skin cancer and take an oral hedgehog-blocking medicine. It may help doctors understand how well these tablets work and how patients do in real life.
This Phase 2 study looks at using a medication that blocks the “Sonic Hedgehog” pathway together with radiotherapy to reduce future problems from locally advanced basal cell carcinoma (BCC). It’s for people whose cancer responded completely to the first Sonic Hedgehog pathway inhibitor treatment and where doctors can confirm that response with a tissue test.
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
This trial tests a combination of two drugs, vismodegib and atezolizumab, for people with non-small cell lung cancer that has spread or come back after standard treatments. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hear when a new Advanced Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.